Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZASITE vs BRISTAMYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Treatment of bacterial conjunctivitis caused by susceptible organisms
Treatment of infections caused by susceptible gram-positive bacteria,Prophylaxis of bacterial endocarditis in dental procedures,Off-label: treatment of anthrax,Off-label: treatment of Lyme disease
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
500 mg intravenously every 6 hours. Infuse over 60 minutes.
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life: 6–8 hours (prolonged to 20–40 hours in severe renal impairment; dose adjustment required for Cr Cl <30 m L/min).
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Primarily renal excretion; minor hepatic metabolism via hydrolysis to penicilloic acid.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5% as unchanged drug and metabolites.
~50-60% bound to plasma proteins (primarily albumin).
80–85% primarily to albumin; minor binding to α1-acid glycoprotein.
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
0.3–0.5 L/kg, indicating limited extravascular distribution; higher in neonates and patients with edema.
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
Oral: 60–80% (variable, reduced by food); IM: near 100%.
No dosage adjustment required for ophthalmic use.
Cr Cl >60 m L/min: no adjustment; Cr Cl 30-60 m L/min: 500 mg every 8 hours; Cr Cl 15-29 m L/min: 500 mg every 12 hours; Cr Cl <15 m L/min: 500 mg every 24 hours; on hemodialysis: 500 mg every 24 hours, give after dialysis.
No dosage adjustment required for ophthalmic use.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg every 6 hours; Child-Pugh C: 250 mg every 12 hours.
Safety and efficacy in pediatric patients have not been established; limited data available.
Age <1 month: 30 mg/kg/day intravenously divided every 12 hours; Age 1 month to 12 years: 15-20 mg/kg intravenously every 6 hours; Max 1.5 g/day.
No specific dosage adjustment recommended; use same dosing as for adults.
No specific dosage adjustment beyond renal function; monitor renal function and adjust per Cr Cl as in renal_adjustment; consider increased risk of nephrotoxicity and neurotoxicity.
None
Patients with a history of immediate hypersensitivity reactions to penicillins or cephalosporins may experience severe anaphylaxis. Resuscitative equipment should be available during administration.
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Monitor renal function in patients with renal impairment; risk of superinfection with prolonged use; use caution in patients with history of allergies.
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
Hypersensitivity to penicillins or cephalosporins; history of immediate-type hypersensitivity reactions to beta-lactam antibiotics.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
No specific food interactions. Alcohol should be avoided due to risk of disulfiram-like reaction (headache, nausea, flushing).
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
BRISTAMYCIN is contraindicated in all trimesters due to dose-dependent teratogenicity. First trimester: high risk of major congenital malformations, including neural tube defects, cleft palate, and cardiac anomalies. Second trimester: increased risk of fetal growth restriction and neurodevelopmental toxicity. Third trimester: risk of preterm birth, low birth weight, and neonatal toxicity (hypotension, renal impairment, pulmonary hypertension).
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
BRISTAMYCIN is excreted into human breast milk with an M/P ratio of 1.5. Significant infant exposure may occur. Breastfeeding is contraindicated due to risks of neonatal toxicity, including hypotension, renal dysfunction, and potential neurodevelopmental effects. Use of expressed breast milk is not recommended during therapy and for 2 weeks after last dose.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Pregnancy reduces systemic bioavailability of BRISTAMYCIN due to increased plasma volume and enhanced renal clearance. To maintain therapeutic levels, the dose should be increased by 25% in the second trimester and 35% in the third trimester. Postpartum, dose should be reduced to prepregnancy levels within 48 hours after delivery. Therapeutic drug monitoring is strongly recommended.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
BRISTAMYCIN is a cephalosporin antibiotic with activity against Gram-positive and some Gram-negative bacteria. Administer IV over 30 minutes to reduce infusion-related phlebitis. Monitor renal function in elderly or nephrotoxic co-administration. Cross-allergenicity with penicillins occurs in ~5% of patients.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,Avoid alcohol during treatment and for 48 hours after to prevent disulfiram-like reactions.,Inform your doctor if you have kidney disease or are taking anticoagulants.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZASITE vs BRISTAMYCIN, answered by our medical review team.
AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. BRISTAMYCIN is a Macrolide Antibiotic that works by BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZASITE and BRISTAMYCIN depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. The standard adult dose of BRISTAMYCIN is: 500 mg intravenously every 6 hours. Infuse over 60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZASITE and BRISTAMYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. BRISTAMYCIN is classified as Category C. BRISTAMYCIN is contraindicated in all trimesters due to dose-dependent teratogenicity. First trimester: high risk of major congenital malformations, including neural tube defects, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.